MEDICAL BIOLOGICAL DEFENSE (APPLIED RESEARCH)
Abstract
This project (TB2) funds applied research on vaccines, therapeutic drugs, and diagnostic capabilities to provide effective medical defense against validated biological threat agents or emerging infectious disease threats including bacteria, toxins, and viruses. Innovative biotechnology approaches will be incorporated to advance medical systems designed to rapidly identify, diagnose, prevent, and treat disease due to exposure to biological threat agents. Categories for this project include core science efforts in biological defense capability areas, such as Pretreatments, Diagnostics, and Therapeutics. Medical Science and Technology (S&T) efforts in this Budget Activity refine promising medical initiatives identified in Budget Activity 1, resulting in the development of countermeasures to protect against and treat the effects of exposure to biological agents. This project includes the Transformational Medical Technologies Initiative (TMTI), (funded as the Transformational Medical Technologies (TMT) program in FY12). The program was launched to respond to the threat of emerging or intentionally engineered biological threats. TMT's mission is to protect the Warfighter from genetically engineered biological threats by providing a rapid response capability from identification of pathogens to the delivery of medical countermeasures. This mission is accomplished through two main efforts: 1) developing broad spectrum (multi-agent) therapeutics against biological agents (e.g. one drug that treats multiple agents); and 2) developing platform technologies to assist in the rapid development of medical countermeasures (MCMs) in response to biological agents (e.g. developing new and innovative ways to mass produce drugs in the event of a biological incident). The Medical Countermeasures Initiative (MCMI) was established to coordinate inter-related advanced development and flexible manufacturing capabilities, based on partnerships between the government and industry, providing a dedicated, cost-effective, reliable, and sustainable MCM process that meets the warfighter and national security needs. Specifically, the MCMI will provide the capability for the advanced development and flexible manufacturing of biological MCM (to include TMT developed MCMs) to address CBRN threats, including novel and previously unrecognized, naturally-occurring emerging infectious diseases. MCMI efforts within S&T are concentrated in two areas: 1) advancement of regulatory science, and 2) advancements in flexible manufacturing technologies for MCMs. In FY13, all Project TB2 research is re-aligned into Project TM2 - Techbase Medical Defense.
Document Details
- Document Type
- Project
- Publication Date
- Oct 01, 2013
- Source ID
- TB2_0602384BP_2_0400_PB_2013
Related Documents
- Root: CHEMICAL/BIOLOGICAL DEFENSE (APPLIED RESEARCH)
- Child Accomplishment: 1) Medical Countermeasures Initiative (MCMI)
- Child Accomplishment: 2) Diagnostics (Biosurveillance)
- Child Accomplishment: 3) Pretreatments
- Child Accomplishment: 4) Pretreatments
- Child Accomplishment: 5) Pretreatments
- Child Accomplishment: 6) Therapeutics
- Child Accomplishment: 7) Therapeutics
- Child Accomplishment: 8) Therapeutics
- Child Accomplishment: 9) Transformational Medical Technologies
- Child Accomplishment: 10) Transformational Medical Technologies
- Child Accomplishment: 11) Transformational Medical Technologies Initiative
- Child Accomplishment: 12) Transformational Medical Technologies Initiative
- Child Accomplishment: 13) SBIR